Next week several SeRMN members will present our research work at the Joint Annual meeting ISMRM-ESMRMB 2014 that will take place in Milan (Italy) from 10th to 16th May. Find below a summary of our contributions.
Organized by the SeRMN of the Autonomous University of Barcelona (UAB).
This workshop combines a comprehensive series of lectures on the technology of Magnetic resonance spectroscopy and imaging (MRS/MRI) with hands-on laboratory sessions to provide practical demonstrations of key concepts and procedures for preclinical studies.
Whether you are considering MRI as a research tool in your lab or just would like to learn more about MRI, this workshop addresses practical aspects of experimental MRI with laboratory animals and provide valuable hands-on experience on a 7 Tesla Bruker BioSpec spectrometer.
Number of participants will be limited to 4.
For the registration, please fill the Registration Form and email it to (registration deadline ends May 27st)
“Brain magnetic resonance in experimental acute-on-chronic liver failure” by L. Chavarria, M. Oria, J. Romero-Giménez, J. Alonso, S. Lope-Piedrafita, and J. Cordoba. Liver International 33 (2013) 294-300. DOI: 10.1111/liv.12032
Liver failure causes brain edema that can lead to intracranial hypertension and death. It is currently uncertain whether this water accumulation is predominantly intracellular or extracellular, something important to determine in order to apply the most adequate therapeutic measures. The aim of this study was to investigate the mechanisms involved in the neurological manifestations occurring in an experimental acute-on-chronic liver failure rat model that combines sustained liver injury with a factor inducing an inflammatory response.
We are recruiting an Early Stage Researcher to work on the Development of Decision Support System & Spectral Classification tool meta-plug-ins for the jMRUI platform as part of the TRANSACT-ITN European project.
We seek a highly motivated and qualified individual as Early Stage Researcher for a three-year applied research project. The successful candidate will contribute to the development of advanced biomedical research tools in the field of Magnetic Resonance Spectroscopy and Imaging, and its application to the clinical day-to-day practice.
The position is intended for a young post-graduate student/researcher, with a Master degree or equivalent on Engineering or Computer Science, and with a proficient knowledge of the Java programming language. Prior experience on signal and/or image processing, segmentation and pattern recognition applications in the field of biomedical research is an asset, particularly in the field of Magnetic Resonance Spectroscopy and/or Imaging.
Transforming Magnetic Resonance Spectroscopy into a Clinical Tool (TRANSACT) is an European research project awarded in the call FP7-PEOPLE-2011-ITN, of the 7th Framework Programme Marie-Curie Actions, to a network of partners including the GABRMN and SeRMN at UAB, and the associated partner CIBER-BBN. The project is coordinated by Prof. Sabine Van Huffel, Prof. Uwe Himmelreich, and Dr. Diana Sima, of the Department of Electrical Engineering ESAT-SCD, and Department of Imaging & Pathology, Biomedical MRI Unit, Katholieke Universiteit Leuven, Leuven, Belgium. Scientist-in-charge at UAB will be Prof. Carles Arús (GABRMN) and Miquel Cabañas (SeRMN), and Dr. Margarida Julià-Sapé will be scientist-in-charge at CIBER-BBN. Dr. Silvia Lope-Piedrafita (SeRMN) will take part in the project as senior scientist.
“Dimethyl sulfoxide (DMSO) as a potential contrast agent for brain tumors”, by Delgado-Goñi T, Martín-Sitjar J, Simões RV, Acosta M, Lope-Piedrafita S, Arús C.; NMR in Biomedicine. 2012.DOI: 10.1002/nbm.2832.
Identifying the type of brain tumor helps doctors determine the most appropriate course of treatment. Brain tumor diagnosis usually involves a neurological examination, brain scans, and/or an analysis of the brain tissue. Nowadays, the biopsy, although it is a very invasive procedure, is the most accurate method of obtaining a diagnosis. Continue reading DMSO as a magnetic resonance contrast agent for brain tumors→